Prevention of
Provided herein are immunogenic compositions and vaccines for the treatment and prevention of Staphylococcus aureus infections. These immunogenic compositions and vaccines comprise combinations of bioconjugates capsular polysaccharides that are N-linked to one or more carrier proteins.
1. A composition comprising a capsular polysaccharide type 8 that is N-linked to clumping factor A (CP8-ClfA), and a second N-glycosylated protein, wherein said clumping factor A comprises one or more recombinantly introduced N-glycosylation consensus sequences and wherein said second N-glycosylated protein is a capsular polysaccharide type 5 alpha toxin (CP5-Hla).
2. The composition of claim 1 further comprising a third N-glycosylated protein.
3. The composition of claim 2 , wherein the third N-glycosylated protein is CP5-Epa, CP8-Epa, CP5-ClfA, or CP8-Hla.
4. A method of treating an infection with Staphylococcus aureus in an animal, comprising a step of administering an immunogenic amount of the composition of claim 1 to said animal.
5. The method of claim 4 wherein the Staphylococcus aureus is Methicillin-resistant Staphylococcus aureus (MRSA).
6. A method of eliciting an antibody response against Staphylococcus aureus in an animal, comprising a step of administering an immunogenic amount of the composition of claim 1 to said animal.
7. The method of claim 4 , wherein the animal is a human.
8. The method of claim 6 , wherein the animal is a human.